Your browser doesn't support javascript.
loading
Clinical Evaluation of Assays for Plasma Renin Activity and Aldosterone Measurement by Liquid Chromatography-Tandem Mass Spectrometry.
Gibbons, Stephen M; Field, Helen P; Fairhurst, April; Fleming, Anne; Ford, Clive; Williams, Emma L; Barnes, Sophie C; Barth, Julian H.
Afiliación
  • Gibbons SM; SAS Laboratory Endocrinology, St James University Hospital, Leeds, UK.
  • Field HP; SAS Laboratory Endocrinology, St James University Hospital, Leeds, UK.
  • Fairhurst A; SAS Laboratory Endocrinology, St James University Hospital, Leeds, UK.
  • Fleming A; SAS Laboratory Endocrinology, St James University Hospital, Leeds, UK.
  • Ford C; SAS Laboratory Endocrinology, St James University Hospital, Leeds, UK.
  • Williams EL; SAS Laboratory Endocrinology (Part of North West London Pathology), Charing Cross Hospital, London, UK.
  • Barnes SC; SAS Laboratory Endocrinology (Part of North West London Pathology), Charing Cross Hospital, London, UK.
  • Barth JH; SAS Laboratory Endocrinology, St James University Hospital, Leeds, UK.
J Appl Lab Med ; 6(3): 668-678, 2021 04 29.
Article en En | MEDLINE | ID: mdl-33928391
BACKGROUND: Aldosterone and renin are pivotal hormones in the regulation of salt and water homeostasis and blood pressure. Measurement of renin and aldosterone in serum/plasma is essential for the investigation of primary hyperaldosteronism (PA) and monitoring of glucocorticoid replacement therapy. METHODS: We report 2 LC-MS/MS methods developed to measure aldosterone and plasma renin activity (PRA). PRA was determined by endogenous enzymatic generation of angiotensin I using 150 µL of sample. Generated angiotensin I was purified by solid phase extraction prior to chromatographic separation and mass spectrometry. Aldosterone measurement required 300 µL of sample extracted with MTBE prior to LC-MS/MS analysis. RESULTS: The PRA method was linear (1.2-193 nmol/L), sensitive (LLOQ = 1.2 nmol/L), precise (CV = 4.1%), and specific (no cross reactivity for a number of structurally similar steroids). Dilutional linearity and recovery (84%) were acceptable. Accuracy was confirmed by comparison against our current RIA method. The aldosterone method had equally acceptable performance characteristics. Reference ranges in 110 healthy normotensive subjects were: PRA 0.2-3.7 nmol/L/h and aldosterone 50-950 pmol/L. Consecutive patients (n = 62) with adrenal incidentalomas shown to have no functional adrenal disease; their post overnight 1 mg dexamethasone test values were: PRA 0.2-2.6 nmol/L/h and aldosterone 55-480 pmol/L. Serum aldosterone values after 2 liter saline suppression were-normal subjects (n = 17): 78-238 pmol/L and confirmed primary hyperaldosteronism (n = 25): 131-1080 pmol/L. CONCLUSIONS: We have developed robust assays for PRA and aldosterone with appropriate clinical evaluation. These assays are now in routine practice in the UK.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de las Glándulas Suprarrenales / Aldosterona Límite: Humans Idioma: En Revista: J Appl Lab Med Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de las Glándulas Suprarrenales / Aldosterona Límite: Humans Idioma: En Revista: J Appl Lab Med Año: 2021 Tipo del documento: Article